Cargando…
Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy
PURPOSE: Approximately 7% of patients with newly diagnosed prostate cancer (PCa) in the US will have have metastatic disease. The dogma that there is no role for surgery in this population has been questioned recently. Here we report long-term outcomes of a phase 1 clinical trial on cytoreductive ra...
Autores principales: | Kim, Isaac Yi, Mitrofanova, Antonina, Panja, Sukanya, Sterling, Joshua, Srivastava, Arnav, Kim, Juliana, Kim, Sinae, Singer, Eric A., Jang, Thomas L., Ghodoussipour, Saum, Saraiya, Biren, Mayer, Tina, Sabaawy, Hatem E., Yuh, Bertram, Byun, Seok Soo, Kim, Wun-Jae, Horie, Shigeo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035380/ https://www.ncbi.nlm.nih.gov/pubmed/35510081 http://dx.doi.org/10.1016/j.prnil.2022.03.001 |
Ejemplares similares
-
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
por: Yuh, Bertram E., et al.
Publicado: (2019) -
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
por: Srivastava, Arnav, et al.
Publicado: (2021) -
Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study
por: Kim, Dae Keun, et al.
Publicado: (2018) -
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
por: Kim, Isaac E., et al.
Publicado: (2019) -
Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)